Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms

Table 7 Performance of several serum non-invasive markers for liver fibrosis (single or combination) as expressed as AUROC

Serum marker	Significant fibrosis	Cirrhosis	Ref.
Hyaluronic acid	0.73-0.92	0.85-0.97	[40–47]
Laminin	0.82	NA	[4849]
Type IV collagen	0.83	NA	[51–53]
MMP-2	0.59	0.97	[54]
TIMP-1	0.71	0.90	[54]
ELF	0.77-0.94	NA	[60–62]
AAR	NA	0.51-0.83	[63–657172]
Forns’ index	0.75-0.86	NA	[67687072]
APRI	0.69-0.88	0.61-0.94	[1564–677276–80]
Fibrotest	0.74-0.87	0.71-0.87	[1565677276–80]
Fibroindex	0.74-0.83	NA	[7172]
Fibrometer	0.89-0.96	NA	[5556]
Fibrospect	0.83	NA	[57]
Fib-4	0.79-0.85	0.80-0.91	[73–75]
Hepascore	0.82-0.85	0.90-0.94	[5859]

AUROC: Area under the receiving operating characteristic curve; MMP-2: Metalloproteinase 2; TIMP-1: Tissue inhibitor of metalloproteinases 1; ELF: European liver fibrosis study group; AAR: AST-to-ALT ratio; APRI: AST-to-platelet ratio index.